Inhibrx Biosciences Ratios (2023-2025) | INBX

Ratios Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
EBT Margin (Quarter) -156,823.33%-43,518.49%-5,628.76%1,858,013.00%-47,865.00%-2,204.00%
EBIT Margin (Quarter) -137,796.67%-38,510.08%-5,403.24%-160,898.00%-49,928.00%-2,106.85%
EBITDA Margin (Quarter) -137,796.67%-38,510.08%-5,403.24%-160,898.00%-49,928.00%-2,106.85%
Operating Margin (Quarter) -137,796.67%-38,510.08%-5,403.24%-160,898.00%-49,928.00%-2,106.85%
Net Margin (Quarter) -156,840.00%-43,520.17%-5,628.52%1,858,011.00%-47,865.00%-2,204.15%
FCF Margin (Quarter) -46,551.26%-3,688.07%-57,258.00%-42,769.00%-2,302.46%
Efficiency
Assets Average (Quarter) 240.49M201.66M211.70M227.38M194.79M161.97M
Asset Utilization Ratio (Quarter) 0.010.010.010.010.01
Leverage & Solvency
Interest Coverage Ratio (Quarter) -5.23-5.62-10.71-9.08-29.80-25.15-4.64-3.15-4.23-5.32
Debt Ratio (Quarter) 0.670.410.470.560.69
Times Interest Earned (Quarter) -5.23-5.62-10.71-9.08-29.80-25.15-4.64-3.15-4.23-5.32
Valuation
Enterprise Value (Quarter) -277.92M-226.86M-196.30M-152.60M-216.52M-186.57M-153.10M-124.20M
Return Ratios
Return on Sales (Quarter) -15.68%-4.35%-0.56%185.80%8.87%-4.79%-0.22%-1.11%-1.00%
Return on Capital Employed (Quarter) -188.30%-205.95%-178.82%-88.63%-96.99%-105.34%
Return on Assets (Quarter) 0.07%0.08%0.08%-0.01%-0.01%-0.01%